On The Horizon

//On The Horizon

Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.

We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to evaluate tumor response, adverse effects, and survival in men with castrate resistant prostate cancer who had exhausted all other potential approved therapies, evaluated the novel radioligand therapy with Lu-PSMA-617. Fifty therapies using Lu-PSMA-617 were performed in 28 consecutive men with mCRPC. Data were retrospectively analyzed [...]

Green Is The Color To Be – Nano-Particle That Will Reveal in Real Time That Our Cancer Treatment Is Working

Not yet in prime time, but hopefully soon to begin in human trials is a simple, but possibly very powerful use of nano-particles that could immediately reveal if our individual chemotherapy or immunotherapy is effective. Not all therapies are effective for each of us and knowing quickly if a therapy is working for any individual is vital. Knowing the efficacy of a therapy, in real time, would allow us to more quickly move on to an alternative therapy, if needed and will allow us to stop an ineffective therapy quickly which in turn will save untold suffering from side effects [...]

More From ASCO GU 2016 – ExoDx™ Prostate(IntelliScore): A More Precise, Genetically Informed Prostate Cancer Test from a Simple Urine Sample

The constant hope and conversation of late has surrounded what is referred to as a liquid biopsy. The hope and goal is to no longer need to have an invasive needle biopsy to diagnose and stage prostate cancer. Biopsies are not accurate because there are too many false negatives, they only evaluate the actual tissue sampled and do not take into consideration the un-sampled tissue (which can have a different type or stage of cancer present). They also are painful and worse expose men to the possibility of infections, some of which can be life threatening. We dream of finding [...]

CTC Heterogeneity Predicts Prostate Cancer Drug Sensitivity

This afternoon I am off to the American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco. There has already been some information leaking to the media about some of the presentations that will be going on at the conference. One such “leak” is about  findings from Memorial Sloan Kettering Cancer Center and Epic Sciences who will be reporting that they have found that greater diversity among circulating tumor cells (CTCs) in the blood (heterogeneity) of men with advanced prostate cancer predicts not only shorter overall survival, but also the development of resistance to anti-androgen therapies. However, [...]